PONY(SZ:300887)2021-04-26 16:00Financial Performance - Revenue for Q1 2021 reached ¥311,601,470.04, an increase of 81.51% compared to ¥171,673,802.07 in the same period last year[7] - Net profit attributable to shareholders was -¥42,567,499.50, a slight improvement of 3.80% from -¥44,249,342.25 year-on-year[7] - Basic and diluted earnings per share improved by 59.91% to -¥0.3112 from -¥0.7763 in the same period last year[7] - The company reported a weighted average return on equity of -2.37%, an improvement of 2.74% from -5.11% in the previous year[7] - The total comprehensive income for Q1 2021 was a loss of CNY 42.57 million, slightly better than the loss of CNY 44.35 million in Q1 2020[47] Cash Flow - Net cash flow from operating activities was -¥121,307,300.07, representing a decline of 68.55% compared to -¥71,972,375.16 in the previous year[7] - Operating cash flow increased by 64.66% to CNY 299,943,668.26 in Q1 2021, primarily due to improved customer payment speed as the impact of the pandemic diminished[20] - The net cash flow from investment activities was CNY -26,404,403.34, reflecting increased outflows for equipment purchases and acquisitions[22] - The net increase in cash and cash equivalents was CNY -147,715,398.94, a decrease of 330.95% due to the combined effects of operating, investing, and financing activities[22] - The company reported a net cash outflow from financing activities of CNY 126,221,529.93, primarily due to bank loan repayments[22] Assets and Liabilities - Total assets increased by 3.78% to ¥2,193,059,161.06 from ¥2,113,141,512.61 at the end of the previous year[7] - Net assets attributable to shareholders decreased by 2.34% to ¥1,778,011,893.51 from ¥1,820,581,823.05 at the end of the previous year[7] - Total liabilities increased to CNY 415,047,267.55 from CNY 292,559,689.56, showing a growth of around 42%[38] - Current liabilities amounted to CNY 267,637,290.93, an increase from CNY 245,888,348.18, representing a rise of approximately 8.5%[38] - Owner's equity totaled CNY 1,778,011,893.51, down from CNY 1,820,581,823.05, indicating a decrease of about 2.3%[39] Operating Costs and Expenses - Operating costs for Q1 2021 were RMB 217.77 million, reflecting an increase of 80.09% from RMB 120.92 million in Q1 2020, primarily due to rising costs associated with increased revenue, including labor, consumables, and equipment depreciation[18] - The company’s management expenses rose by 42.84% to RMB 44.13 million, compared to RMB 30.89 million in the previous year, driven by increased depreciation and management support costs[19] - Total operating costs for Q1 2021 were approximately CNY 363.20 million, an increase from CNY 222.92 million in the same period last year, representing a growth of 63%[45] Investments and R&D - Research and development expenses for Q1 2021 amounted to RMB 28.95 million, a 59.04% increase from RMB 18.20 million in Q1 2020, reflecting the company's commitment to enhancing R&D capabilities[19] - The company plans to invest CNY 150,000,000 in the construction of a new headquarters and R&D center in Shandong[25] - The company has acquired three medical testing laboratories, which contributed to the increase in investment cash outflows[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,017[11] - The largest shareholder, Song Wei, holds 52.27% of the shares, totaling 39,725,000 shares[11] Other Financial Metrics - Non-recurring gains and losses amounted to ¥7,105,128.64, primarily from government subsidies and investment income[9] - The company incurred financial expenses of CNY -276,115.52, a significant decrease from CNY 1.45 million in the previous year, indicating improved financial management[45] - Other income for the quarter was CNY 9.95 million, compared to CNY 8.32 million in the same period last year, reflecting a growth of 19.6%[45]